Home Blog Page 472

GIMME Beauty Sees Major Growth in 2022, Now Carried in Over 15,000 Retail Locations Nationwide

By
NT Editor
-
0
GIMME Beauty Sees Major Growth in 2022, Now Carried in Over 15,000 Retail Locations Nationwide
GIMME is up 80% year-over-year, and the company expects to be carried in over 20,000 locations by January 2023.

SALT LAKE CITY - December 8, 2022 - (Newswire.com)

GIMME Beauty, the innovative hair solutions company disrupting the beauty industry, announces a successful year marked by significant growth through 2022. According to market research company IRI, GIMME is up 80.2% year-over-year (YOY) and currently carried in 15,000 retail locations across the U.S.

Nielsen marketing research data also revealed that GIMME's product line ranks among the fastest-growth items in the industry, and by January 2023, GIMME is expected to surpass 20,000 locations nationwide. Since its launch in 2006, GIMME has grown into a national brand, with retail partners like ULTA, Dillards, Target, CVS and Walgreens set to carry GIMME products in 2023.

"It's been a great year for GIMME, and we're optimistic about what the future holds," said Jeff Durham, CEO of GIMME Beauty. "We look forward to continuing this momentum into 2023. We're grateful to our retail partners for trusting our team as thought leaders. The increase in distribution makes the brand more accessible to more of our growing fans."

GIMME Beauty's accessories are some of the strongest-selling accessories at ULTA, and as such, GIMME has been recognized among ULTA's top-performing accessories brands in 2022.

A Global Hair Tie Market Research Report for 2022 by Market Research Guru takes a deep look into the Hair Tie market, its major players, trends and growth drivers, and provides a forecast of the industry through 2029; the report identifies GIMME as a key player in the market.

GIMME aims to close out 2022 strong with new products slated for December: the GIMME Twist™ shower hair towel, available in blue and gray, and the GIMME Vented Styling and Detangling Brush. GIMME Twist™ dries hair with zero heat damage, and its microfiber material creates a frizz-free style for any hair type while preventing breakage. The towel is fitted with two buttons, allowing for a custom fit for all hair types, lengths and thicknesses. The vented brush is the next in the series of GIMME's premium brushes.

To learn more about GIMME Beauty, visit www.gimmebeauty.com.

About GIMME Beauty

GIMME Beauty's vision is to design innovative hair solutions that disrupt the status quo of the health and beauty hair care category. The company's products rank among the industry's fastest-growth items, according to Nielsen Market Data. Since it launched in 2006, GIMME has become a national brand available at more than 16,000 stores across the United States. Follow GIMME on Instagram or Facebook to learn about its latest collections. To learn more about GIMME Beauty, visit www.gimmebeauty.com.


Contact Information:
Madeleine Moench
[email protected]


Press Release Service by Newswire.com

Original Source: GIMME Beauty Sees Major Growth in 2022, Now Carried in Over 15,000 Retail Locations Nationwide

Physicians for Informed Consent Sues State of California, Argues That Doctor Censorship Bill AB 2098 Violates the U.S. Constitution

By
NT Editor
-
0
Physicians for Informed Consent Sues State of California, Argues That Doctor Censorship Bill AB 2098 Violates the U.S. Constitution
Federal Court to weigh controversial bill that PIC argues is an unlawful targeting of scientific dissent as 'misinformation'

NEWPORT BEACH, Calif. - December 7, 2022 - (Newswire.com)

Physicians for Informed Consent (PIC), an educational nonprofit organization focused on science and statistics, has filed a First Amendment free speech lawsuit (2:22-cv-02147) in the United States District Court for the Eastern District of California, and request for preliminary injunction, against the State of California and Osteopathic Medical Board of California in order to protect the free speech of all physicians in California.

The Plaintiffs are PIC and one of its founding members, physician LeTrinh Hoang, D.O., together with Children's Health Defense, California Chapter. The legal team managing the case are Rick Jaffe, Robert F. Kennedy Jr., and Mary Holland.

The lawsuit argues that the State has weaponized the vague phrase "misinformation," thereby unconstitutionally targeting physicians who publicly disagree with the government's public health edicts on COVID-19.

Expert cardiologist and PIC member Sanjay Verma, M.D., has been tracking and cataloging CDC errors in real time. For the case, he has provided what he calls "a detailed declaration exposing the government's scientific errors and the constitutional dangers of censoring dissent":

"To demonstrate these points of vagueness and the general unsuitability of using 'contemporary scientific consensus' as a disciplinary criterion, I have prepared a detailed overview of public health response to the pandemic broken down into categories such as Masks and Vaccines (transmission, safety, efficacy of natural immunity). I have also included evidence of what [I testify] would be considered misinformation promulgated by the CDC as well as its withholding of information which led to the then 'contemporary scientific consensus' eventually being proven wrong."

PIC President Shira Miller, M.D., was active in opposing AB 2098 while it was navigating the California legislative process, and has led the effort to bring the instant lawsuit. Opposing the bill, she wrote, "Public health is not achieved, and scientific knowledge does not progress, by censoring dissenting physicians and surgeons or anyone else. AB 2098 is anti-doctor, anti-public health, anti-science, and anti-free speech."

The scheduled hearing on PIC's motion for preliminary injunction is Jan. 17, 2023. PIC has requested the District Court issue a preliminary injunction that "AB 2098 is unconstitutional on its face." The Complaint also requests the Court "issue a declaratory judgement that PIC and CHD patient members have a privacy right in their prescriptions for any off-label FDA approved medication" such as ivermectin and hydroxychloroquine. 

Physicians for Informed Consent is a 501(c)(3) tax-exempt nonprofit educational organization supported only by the generous contributions of our members and supporters. Click here to make a contribution.


Contact Information:
Greg Glaser
General Counsel
[email protected]
925-642-6651


Press Release Service by Newswire.com

Original Source: Physicians for Informed Consent Sues State of California, Argues That Doctor Censorship Bill AB 2098 Violates the U.S. Constitution

What to Do if You’re Low on Funds in 2023

By
NT Editor
-
0
What to Do if You’re Low on Funds in 2023
LOS ANGELES - December 7, 2022 - (Newswire.com)

iQuanti: With inflation at record highs and the Federal Reserve raising interest rates at an unprecedented pace, many economists are expecting the U.S. to be in a recession throughout most of 2023. If you're concerned about your finances getting tight, then it will be important to know your options. From low-interest credit cards to title loans, there are several ways to get the cash you need. Here are five solutions for the next time you're low on funds. 

1. Squeeze your budget

Everybody has fat in their spending that could stand to be trimmed. And when finances are running dry, this is the first place you should look. You can start by pulling up your bank and credit card statements. Make a note of any expenses that are unnecessary and commit to cutting some or all of them out of your budget.

2. Use 0% APR credit cards

If you absolutely have to make purchases but can't afford to pay them off right away, then something that might help is 0% APR credit cards. These are cards that offer an introductory period of 12 to 24 months where borrowers don't have to pay any interest on their purchases.

If you've already made some purchases on your current credit card, then you can also use these 0% APR cards to perform a balance transfer. This is effectively using one credit card to pay off another with the benefit that the 0% APR card will not accumulate any interest.

3. Apply for a short-term personal loan

Short-term personal loans are another relatively easy place for consumers to get the money they need without a lot of hassle. Many have a fixed rate of interest and last anywhere from two to five years.

Personal loans can be either secured or unsecured. Secured loans require you to offer collateral - something of value like a house or vehicle that the lender can take if you default on your payments. Unsecured loans don't require collateral, but applicants generally need to have a higher credit score.

4. Consider a title loan

If your credit score is not great, then another loan option you can consider is a title loan. With these secured loans, the borrower offers their vehicle as collateral. Title loans can often be approved in minutes. You can typically receive 25 to 50 percent of your car's value and can continue driving your car while you repay the loan.

5. Borrow against your retirement plan

If you've exhausted all other options, one last place you could go to find the money you need is an employer-sponsored retirement plan like a 401(k). Many plans offer participants the ability to borrow as much as $50,000 from themselves. You'd then have to pay the loan back within five years, making payments at least once each quarter, and with interest. Of course, taking money out of your 401(k) will inhibit its growth. So, this could be considered an option of last resort.

The bottom line

With inflation up and the stock market down, money may get tight in 2023. If that happens, start by taking a hard look at your budget before going external to credit cards, personal loans, and title loans. And if all else fails, remember that you do have the option to borrow from your 401(k) retirement plan.


Contact Information:
Keyonda Goosby
Public Relations Specialist
[email protected]
(201) 633-2125


Press Release Service by Newswire.com

Original Source: What to Do if You're Low on Funds in 2023

Riboscience ESMO I/O Presentations Highlight RBS2418 Phase 1 Study Design and the First Human Data From the Evaluation of an ENPP1 Inhibitor for Immune Activation

By
NT Editor
-
0
Riboscience ESMO I/O Presentations Highlight RBS2418 Phase 1 Study Design and the First Human Data From the Evaluation of an ENPP1 Inhibitor for Immune Activation
SUNNYVALE, Calif. - December 7, 2022 - (Newswire.com)

Riboscience, LLC, a private clinical-stage biotechnology company leveraging a proprietary library of nucleoside and non-nucleoside analogues to rationally design drug candidates that are highly efficacious and highly selective for essential targets in the virology and oncology spaces, today announced the publication of two abstracts that will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2022, taking place virtually and on-site in Geneva, Switzerland, from Dec. 7-9, 2022.

Abstract #195TiP outlines the trial design for the Phase 1 clinical evaluation of orally administered RBS2418, a potent and selective ENPP1 inhibitor.  ENPP1 inhibition results in the protection of immune-activating cGAMP and ATP from hydrolysis in the TME and in the reduced production of immune-suppressive adenosine. The ongoing study is a Phase 1a/b, open-label, non-randomized study in patients (pts) (≥18 years) with advanced, unresectable, recurrent or metastatic solid tumors, who have progressed on, or are ineligible for standard therapies. The study begins with dose-escalation where in a 3+3 fashion, pts will receive in one cohort RBS2418 starting at 100mg bid as monotherapy and in a second cohort RBS2418 in combination with Pembrolizumab (200 mg IV q3w). The study will enroll up to 64 pts at 10 sites in the U.S. The primary objectives of the study are safety, tolerability, ENPP1 inhibition and cGAMP protection of RBS2418 as monotherapy and in the combination setting. Immune biomarkers predictive of anti-tumor responses will be explored as well as translational analyses will be done to explore the depth and breadth of immune activation both in tumor tissue and blood. This study is being funded by Riboscience, LLC. 

Abstract#169P summarizes the PK, PD and immunomodulatory profile of RBS2418, which is also the first-in-human experience with an ENPP1 inhibitor. This was an expanded access study in a patient with advanced adrenal cancer, who had previously progressed on a treatment with pembrolizumab and cabozantinib. The results showed that weekly intra-patient escalation of doses from 100 mg BID to 400 mg BID in combination with pembrolizumab was safe, well tolerated with no DLTs. RBS2418 PK data showed oral bioavailability with plasma levels leading to complete serum ENPP1 inhibition at all time points already at the 100 mg starting dose level. The treatment induced increases in peripheral cDCs, proliferation of CD4 and CD8 T cells and hyperexpansion of TCR clonotypes in peripheral blood as well as upregulation of T cell cytotoxic granule protein gene expression, consistent with a treatment-induced immune activation from a baseline cold tumor phenotype. These results support further clinical development of this novel first-in-class immunotherapy agent in the on-going Phase1a/b clinical trial described above (NCT05270213).

 
 
 
Abstract Title Poster Presentation Date/Time (CET)/Location
A First-In-Human, Phase 1 a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Unresectable, Recurrent or Metastatic Tumors (NCT05270213) #195TiP December 8/12:30 p.m./ Foyer ABC Palexpo exhibition center, Geneva
Immunomodulatory effects of RBS2418, an oral ENPP1 inhibitor in combination with pembrolizumab in checkpoint-refractory metastatic adrenal cancer  #169P December 8/12:30 p.m./ Foyer ABC Palexpo exhibition center, Geneva

About Riboscience, LLC.
Riboscience applies specialized chemistry and biology to create novel treatments for human diseases. We particularly focus on building ribose-based molecules, and we use structure-guided design to generate highly selective and efficacious drug candidates.

Nucleoside analogs are examples of ribose-based molecules that have become important drugs for the treatment of a number of viral diseases and cancers. The Riboscience library of nucleoside and non-nucleoside molecules is rationally designed to deliver drug candidates that are highly efficacious and highly selective for essential targets in the virology and oncology spaces.

About RBS2418.

RBS2418 is a nucleoside-derived small molecule that has been optimized for potent (picomolar binding affinity) and selective binding to the active site of ENPP1. ENPP1 is the only enzyme known in humans to hydrolyze the immune-activating messenger molecule cGAMP that is generated in tumor cells in the context of replication errors, DNA damage and a variety of replication defects. ENPP1 also hydrolyzes ATP and contributes to the generation of increased immune-suppressive adenosine levels in the TME. ENPP1 upregulation is commonly observed in tumors and is associated with immune evasion, cold tumor phenotype, disease progression and non-response to checkpoint inhibitors. RBS2418 is the first clinical-stage ENPP1 inhibitor and is being investigated in a Phase 1a/b dose escalation and expansion study as monotherapy and in combination with Pembrolizumab. Refer to the clinicaltrials.gov overview for more information:  RBS2418 Evaluation in Subjects With Unresectable or Metastatic Tumors - Full Text View - ClinicalTrials.gov. For additional information, please visit https://www.Riboscience.com. 

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated," and "intend" or other similar terms or expressions that concern Riboscience expectations, strategy, plans or intentions. These forward-looking statements are based on Riboscience's current expectations and actual results could differ materially. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Riboscience, LLC does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Riboscience Contact:

Jill Jene, Ph.D., MBA

Chief Business Officer

[email protected]


Contact Information:
Jill Jene
CBO
[email protected]


Press Release Service by Newswire.com

Original Source: Riboscience ESMO I/O Presentations Highlight RBS2418 Phase 1 Study Design and the First Human Data From the Evaluation of an ENPP1 Inhibitor for Immune Activation

MIA Recoveries, Inc. Announces That the Mystery of 13 American WWII MIAs is Solved

By
NT Editor
-
0
MIA Recoveries, Inc. Announces That the Mystery of 13 American WWII MIAs is Solved
MIA Recoveries, Inc. has located a long-missing US Air Force C-46 aircraft lost during WWII with 13 souls aboard, bringing to a total of 279 MIA personnel now located.


1st Lt. William Scherer in Local Newspaper in 1943
Picture of Lt. William Scherer, one of the passengers aboard US Air Force C-46A that was declared missing for over 76 years.

PRESCOTT, Ariz. - December 7, 2022 - (Newswire.com)

Clayton Kuhles of MIA Recoveries, Inc. announced a successful expedition and discovery of the location of US Air Force C-46A #42-96721, missing in action since 1945 when it was lost while on a mission during WWII.

"This brings closure to the families after 77 years," said Clayton Kuhles, founder and president of the private, nonprofit MIA Recoveries, Inc.

After first hearing of MIA Recoveries, Bill Scherer, the son of passenger 1st Lt. William Scherer, contacted Clayton to ask if he would look for his father's lost aircraft. 

"After we found the crash site and positively identified it," said Clayton, "Bill said that he wished his mother was still alive to hear this great news. She was heartbroken for decades after her husband disappeared."

It Simply Disappeared

The plane was on a routine flight from China to its base in India. On board was a crew of four and nine passengers.  The weather was very bad, with severe turbulence, violent updrafts and crosswinds, and moderate to severe icing along the entire route.  At 1420Z, contact with the aircraft was lost and it was declared missing in flight. This aircraft was never heard from again.

According to the official Missing Air Crew Report, "It simply disappeared". The plane's nickname was Stork. Dead: 13

Read the official aircraft report and view photos of the expedition at: https://www.miarecoveries.org/c46a-42-96721/

Bringing Closure

MIA Recoveries, Inc. has been searching for, locating, and recovering MIA American airmen since 2002. Clayton Kuhles and his team have reached 27 crashed aircraft missing for decades, thereby accounting for 279 personnel listed as MIA until then.

Finding Lost Aircraft Previously Listed as Unrecoverable

The U.S. lost hundreds of aircraft in the China-Burma-India theater of operations during WWII. The location of these aircraft and the MIA's remains had previously been deemed "Unrecoverable" by the U.S. Dept. of Defense, due to extreme terrain and no precise known locations where these aircraft went down.

"The reason why these cases are unsolved is because they're so remote and so difficult to get there that most people don't want to make an attempt, much less go there," says Clayton. "These people (families of the missing airmen) don't have closure because no one wants to go there."  See the full interview on YouTube 

More MIAs Can Be Brought Home

Clayton says that his MIA expeditions are mostly self-funded and he receives no funding assistance from the U.S. government. He would be able to bring home more American MIAs and bring closure to the families of even more veterans with funding support. A tax-deductible funding donation to MIA Recoveries, Inc. will help fund these ongoing MIA expeditions and bring closure to more families.

MIA Recoveries, Inc. is a tax-exempt public charity under section 501(c)(3) of the Internal Revenue Code. Funding donations to MIA Recoveries, Inc. are tax-deductible.

For more information on MIA Recoveries, Inc.:

https://www.miarecoveries.org/


Contact Information:
Clayton Kuhles
President
[email protected]
928-899-1614


Press Release Service by Newswire.com

Original Source: MIA Recoveries, Inc. Announces That the Mystery of 13 American WWII MIAs is Solved

‘Little Angel’ Launches on Kidoodle.TV® and Catapults to Top of Watch List

By
NT Editor
-
0
‘Little Angel’ Launches on Kidoodle.TV® and Catapults to Top of Watch List
Moonbug Entertainment's wildly popular preschool show dominates fall launch offering on Safe Streaming™ service, Kidoodle.TV

CALGARY, Alberta - December 7, 2022 - (Newswire.com)

Kidoodle.TV, owned by A Parent Media Co. Inc. ("APMC"), announced today the recent launch of the highly successful brand, "Little Angel" from Moonbug Entertainment. With English-language episodes currently available on the Safe Streaming™ service to audiences in the U.S. and Canada, the series will soon be rolling out to other territories, including Australia, New Zealand and Latin America, over the coming months.

"Little Angel," which launched on Kidoodle.TV on Sept. 22, 2022, is an animated, preschool, comedy-based series that explores the wacky and fun reality of growing up through the adventures of Baby John and his family. The show has been captivating families around the world with its irreverent humor, catchy and upbeat songs, and nursery rhymes that kids and parents relate to and love.

The addition of the hit brand "Little Angel" to the Kidoodle.TV service represents the latest in a series of successful collaborations between Moonbug Entertainment and APMC. With an extensive offering of Moonbug content, including "Blippi Wonders," "Lellobee City Farm," "Gecko's Garage," "Oddbods," "T-Rex Ranch," and "Blippi", Kidoodle.TV is pleased to populate its library with such a great lineup. 

"Little Angel" is a widely popular brand worldwide, with 106 million subscribers across all "Little Angel" YouTube channels. It appeared as #1 in Kids Shows on UK Netflix (week of Nov. 1, 2022) and as #4 in Kids Shows on U.S. Netflix (week of Nov. 1, 2022).

"The relationship we have with Moonbug is of immense value because of its focus on today's relevant brands, which are highly sought out by our audience at Kidoodle.TV. The ability to ideate and plan for the big launches together is a value add to both companies and most importantly, to the children and families who we serve and who love these shows," remarked Brenda Bisner, the Chief Content Officer at APMC.

"We are excited to bring Little Angel to Kidoodle.TV's audiences, following on from the success of our other shows on the platform," commented Andy Yeatman, the MD of the Americas for Moonbug Entertainment. "We are looking forward to our continued partnership with APMC and bringing the joy and fun of Moonbug to other territories soon."

With both episodic and compilation formats, Kidoodle.TV audiences will see continued launches of over 10 hours of "Little Angel" videos in English, Spanish, and Portuguese over the coming months. 

—

About APMC and Kidoodle.TV®

Kidoodle.TV® is a family-focused Safe Streaming™ service committed to ensuring children have a safe alternative to stream their favorite TV shows and movies. Available in over 160 countries and territories on thousands of connected devices, Kidoodle.TV provides peace of mind with every show available on Kidoodle.TV strictly vetted by caring people committed to Safe and Free Streaming for Kids™. Kidoodle.TV is available on over 1000 streaming media devices, including iOS, Android, Apple TV, Fire TV, LG, Samsung, VIDAA-enabled Hisense TVs, Chromecast, Roku, Vizio SmartCast, Amazon, Jio, Xfinity X1, Connected TVs, and HTML5 Web. Kidoodle.TV is owned and operated by A Parent Media Co. Inc., a family-based company. Kidoodle.TV is certified by the kidSAFE® Seal Program and is the proud recipient of the Mom's Choice Award®, a Stevie® Award, platinum winner of the Best Mobile App Award, and Parents' Picks Award - Best Elementary Products. Visit www.kidoodle.tv to learn more. 

*Content availability varies by location.

Facebook:          facebook.com/kidoodletv
Twitter:               twitter.com/kidoodletv
Instagram:         instagram.com/kidoodletv

About Moonbug Entertainment

Moonbug Entertainment is an award-winning global entertainment company behind some of the most popular kids' titles in the world. Moonbug's line-up includes global sensations CoComelon, Blippi, Little Baby Bum, Little Angel, My Magic Pet Morphle, Supa Strikas, Go Buster, Playtime with Twinkle, Gecko's Garage, ARPO and many more.

Moonbug's shows are currently available in 32 languages and feature on more than 150 platforms globally, including YouTube, Netflix, Amazon Prime Video, Sky, Super RTL, BBC iPlayer, HBO Max, Tencent, Youku and Roku. The company's portfolio currently stands at 29 IPs and 100+ brand partners.

Moonbug is a subsidiary of Candle Media, an independent, creator-friendly home for cutting-edge, high-quality, category-defining brands and franchises. By bringing together elite talent operating at the intersection of content, community, and commerce, it helps to position leading entertainment businesses for accelerated, sustainable growth in the current market and beyond. Candle is run by its Co-Chairmen and Co-CEOs, leading entertainment executives Kevin Mayer and Tom Staggs, and backed by investment capital from funds managed by Blackstone's flagship private equity business.


Contact Information:
Madeleine Moench
[email protected]


Press Release Service by Newswire.com

Original Source: 'Little Angel' Launches on Kidoodle.TV® and Catapults to Top of Watch List

Home Assist Health: 10 Signs Senior Relative May Need In-Home Care

By
NT Editor
-
0
Home Assist Health: 10 Signs Senior Relative May Need In-Home Care
Holidays Are Perfect Time to Check on Well-Being of Seniors


Sara Wilson
CEO of Home Assist Health

PHOENIX - December 7, 2022 - (Newswire.com)

With holidays just around the corner, many families are gathering or visiting senior relatives, creating the perfect opportunity to check on the well-being of aging seniors. Travel has been limited the past few years for many families, so some signs that your aging loved ones may need in-home care may have gone unnoticed. 

Sara Wilson, CEO of Home Assist Health, a Phoenix-based nonprofit that serves 1,200 seniors and individuals with disabilities in their homes annually, notes, "Seniors often don't want to ask for help because they are afraid of being put in a long-term care home or being moved from where they are most comfortable, their homes. The good news, many families don't realize seniors can stay in their own home and have help come to them." 

Wilson shares that if you visit senior family members this holiday season and notice the following, it may be time to have a conversation about home care:

10 Signs Your Senior Relative May Need In-Home Care

  1. Not keeping up with house cleaning/yard work
  2. Missing appointments or meetings/obligations
  3. Poor personal hygiene or bladder control issues
  4. Difficulty with mobility or standing
  5. Car accident or difficulty driving
  6. Depression, seclusion or changes in mood
  7. Loss of interest in activities they used to enjoy
  8. Multiple chronic illnesses they are trying to manage, like diabetes or high blood pressure
  9. Gained or lost a significant amount of weight; trouble chewing, swallowing or taking medication
  10. Recent fall

Next Steps for Care

If concerned, consider taking the next step by contacting organizations like Home Assist Health that provide free phone interviews and in-home evaluations. Determine if a loved one has insurance for home care, which may come from a Medicaid Long-Term Care benefit, Select Medicare Advantage Plans, or Private Long-Term Care Insurance Plan. For those without home care benefits from insurance, there are other payment methods for accessing care at home. Visit https://homeassisthealth.org to learn more.

About Home Assist Health

Home Assist Health, a nonprofit organization based in Phoenix, offers personalized home- and community-based services to seniors and individuals with disabilities. Services include personal care assistance, companionship, housekeeping, respite care and habilitation. Specialty services include enhanced care transitions and enhanced chronic disease management. Home Assist Health puts compassion into action, supporting Arizonans in building and maintaining their independence, community involvement and overall life quality while remaining in the comforts of their own home. More info: https://homeassisthealth.org or follow them on Facebook and LinkedIn.


Contact Information:
Heidi Goitia
PR for Home Assist Health
[email protected]
928-220-1747


Press Release Service by Newswire.com

Original Source: Home Assist Health: 10 Signs Senior Relative May Need In-Home Care

Pray.com Named to Inc.’s 2022 Best in Business List for General Excellence

By
NT Editor
-
0
Pray.com Named to Inc.’s 2022 Best in Business List for General Excellence
3rd annual list recognizes 241 private companies putting purpose ahead of profit


Pray.com logo
Black Pray.com logo

LOS ANGELES - December 7, 2022 - (Newswire.com)

Pray.com has been named to the Inc. 2022 Best in Business list in the General Excellence category. This award honors companies that have made an extraordinary impact in their fields and society. Pray.com is the first religious media company to be recognized for this award.

The list, which can be found in the Winter issue of Inc. magazine (on newsstands December 13), recognizes the most dynamic companies of all sizes and industries that have had an outstanding influence on their communities or their industries.  

Scott Omelianuk, editor-in-chief of Inc., says, "Inc. magazine is dedicated to showcasing America's most dynamic businesses and the great things they do. The Best in Business Awards shine a light on those that have gone above and beyond their original mission to make a social, environmental or economic impact, benefiting those around them."

Rather than relying on quantitative criteria tied to sales or funding, Inc.'s editors reviewed the companies' achievements over the past year and noted how they made a positive difference in the world. They then selected honorees in 55 categories - from advertising to sustainability to retail, and more - and in age-based, revenue-based, size-based, and impact-based categories. The applicant pool was extremely competitive - a huge success for the 241 honored in the list's third year. Honorees for general excellence across various industries and categories are featured online at inc.com/best-in-business.

"We are honored to have been recognized by Inc. not just for a standard of excellence, but for how we combine profit and purpose at Pray.com. At Pray.com, prayer is the priority. As the world's #1 app for daily prayer, Pray.com strives to help people grow faith, cultivate community, and leave a legacy of helping others," said Pray.com founder and CEO Steve Gatena. "Pray.com appreciates Inc.'s efforts to bring attention to social impact companies, and we are grateful to be listed at the top."

About Pray.com
Pray.com was launched in 2017 with a mission to grow faith and cultivate community. Today, Pray.com is the world's No. 1 app for daily prayer and faith-based audio content. In addition to helping people make prayer a priority with its mobile app, Pray.com produced the Bible in Year podcast, which hit #1 on Spotify in the religion category. Every day, Pray.com provides millions of people with encouragement and inspiration through daily devotionals, sermons from pastors, and Bedtime Bible Stories. See more at www.pray.com/discover.

ABOUT INC.
The world's most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community they need to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. For more information, visit www.inc.com.


Contact Information:
Melany Ethridge
[email protected]
(214) 912-8934


Press Release Service by Newswire.com

Original Source: Pray.com Named to Inc.'s 2022 Best in Business List for General Excellence

Purpose Healing Center Opens New State-of-the-Art Detox Center in Phoenix

By
NT Editor
-
0
Purpose Healing Center Opens New State-of-the-Art Detox Center in Phoenix

Recreational Area
Purpose Healing Center Detox Facility Recreational Area

PHOENIX - December 7, 2022 - (Newswire.com)

Purpose Healing Centers is excited to announce the opening of a new state-of-the-art detox center in Phoenix. It is located at 1841 N. 24th Street, Phoenix, AZ, 85008, and is accepting new patients now. The new facility offers industry-leading approaches to drug and alcohol detoxification in a peaceful environment. As patients undergo their detox processes, they will be comfortable in generously large bedrooms with comfortable furnishings, allowing them to rest and heal. Each room has a private bath and shower, and a personal TV.

Purpose Healing Centers focus on the health of patients, physically, emotionally, and mentally. Each room is designed to prevent injury or self-harm. Patients have 24-hour access to nursing staff and they are provided care uniquely tailored for their symptoms.

They offer full drug and alcohol detox services, working in partnership with the treatment services offered at their other campuses, including inpatient recovery, IOP, PHP, outpatient and family therapy.

The new facility offers patients private rooms and two recreational areas with larger TVs and other entertainment. There are also two outdoor areas for cigarette smoking. The 16,000-square-foot facility is equipped with multiple nursing stations, so patients always have help available for their care. Nutrition is important when healing during detox, and hot meals tailored to the nutritional needs of those in recovery are provided, as well as snacks.

Why Detox Is Necessary for Addiction Therapy

Many people don't realize that the highest chance for someone to relapse is within the first week of deciding to get sober. For some substances, withdrawal without medical supervision can be deadly, for example, alcohol and benzodiazepines.

Purpose Healing Center administers medically managed and supervised withdrawal from drugs and alcohol. Patients are monitored around the clock for emergencies and to assess their progression. 

Once the body is cleansed of the substances, the patient is in a better place to start the work of sobriety and rehabilitation. A good experience in the detox part of recovery can be critical to the success of each patient and establish them on a path of health and wellness. 

Mission

Purpose Healing Center was born with this in mind: "Bring Addiction Treatment to as many people as possible and save lives." Robin Byrne, LCSW, Chief Clinical Officer and Cofounder of Purpose Healing Centers.

They approach addiction treatment holistically, exploring the underlying reasons why patients drink or use drugs. Services are provided by licensed and professionally trained counselors and therapists, and there are a variety of programs, including professional counseling, group therapy, and learning about the science of addiction.

Do You or Someone You Love Need Drug or Alcohol Detox?

No matter how severe the addiction, there is hope and help. It starts with a phone call to a compassionate counselor at Purposes Healing Center. Call (480) 579-3319 today.


Contact Information:
Briana Kay
Marketing coordinator
[email protected]
5165871400


Press Release Service by Newswire.com

Original Source: Purpose Healing Center Opens New State-of-the-Art Detox Center in Phoenix

Dynapower to Support World’s Largest Green Hydrogen Storage Project

By
NT Editor
-
0
Dynapower to Support World’s Largest Green Hydrogen Storage Project

Advanced Clean Energy Storage
Simple notional diagram of the Advanced Clean Energy Storage hub green hydrogen project.

SOUTH BURLINGTON, Vt. - December 7, 2022 - (Newswire.com)

Dynapower, a Sensata Technologies company and a global leader in power conversion and energy storage solutions, announced that it has been selected to provide 220 megawatts of IGBT chopper rectifiers to the Advanced Clean Energy Storage hub—powering the production of green hydrogen to accelerate the decarbonization of the Western United States.

Located in Delta, Utah, the Advanced Clean Energy Storage hub will be the world's largest renewable energy storage facility. The hub will capture excess wind and solar energy and—with the help of Dynapower's power conversion systems—convert it to green hydrogen using electrolysis and store it in underground salt caverns. The first two caverns at the hub will store up to 300-gigawatt hours of dispatchable clean energy and feed it back to the grid when it's most needed.

Dynapower's high-power, highly reliable IGBT chopper technology was chosen for this project due to several key advantages, including a high power factor across the input range, compliance with IEEE 519 grid harmonics, a simplified and lower-cost transformer design, low DC ripple, and a rapid response to changes in power generation.

"We're thrilled to support this project and expand the use of clean hydrogen to decarbonize the energy ecosystem," said Adam M. Knudsen, Chief Executive Officer of Dynapower. "Our commitment to advancing a clean energy future is stronger than ever, and we're honored to be able to contribute our expertise to a renewables project of this size and magnitude, paving the way for the future of green hydrogen power and a cleaner planet."

Dynapower brings 60 years of experience in power electronics, U.S.-based manufacturing, world-class service and support, and a proven track record of successful execution to the Advanced Clean Energy Storage hub project. More information about the hub can be found at https://aces-delta.com.

###

About Dynapower

Since 1963, Dynapower, a Sensata Technologies company, has provided power electronics solutions, along with an array of aftermarket services focused on continuous reliability and efficiency to an ever-expanding global customer base. Dynapower is a trusted leader in all types of power conversion equipment including high-power rectifiers, inverters, DC/DC converters, integrated battery energy storage systems, and transformers for use in hydrogen, e-mobility, energy storage, industrial, mining, defense, and research applications. With headquarters and a 150,000-square-foot vertically integrated manufacturing facility in South Burlington, VT, Dynapower is collaborating with its partners and clients to shift the way our world uses power and advance our resilient, clean energy future. Learn more at dynapower.com.

About Sensata Technologies

Sensata Technologies is a global industrial technology company striving to create a cleaner, more efficient, electrified and connected world. Through its broad portfolio of sensors, electrical protection components and sensor-rich solutions which create valuable business insights, Sensata helps its customers address increasingly complex engineering and operating performance requirements. With more than 21,000 employees and global operations in 13 countries, Sensata serves customers in the automotive, heavy vehicle & off-road, industrial, and aerospace markets. Learn more at www.sensata.com.


Contact Information:
Jenifer Audette
Marketing Manager
[email protected]
(802) 652-1383
Related Images
Advanced Clean Energy Storage
Advanced Clean Energy Storage
Simple notional diagram of the Advanced Clean Energy Storage hub green hydrogen project.



Press Release Service by Newswire.com

Original Source: Dynapower to Support World's Largest Green Hydrogen Storage Project
1...471472473...579Page 472 of 579
© Newsmag WordPress Theme by TagDiv